首页> Drug Development Research> DPP‐4 inhibitor linagliptin ameliorates imiquimod‐induced psoriasis‐like skin alterations in type 2 diabetic mice by inhibiting the MAPK/NF‐κB inflammatory pathway

DPP‐4 inhibitor linagliptin ameliorates imiquimod‐induced psoriasis‐like skin alterations in type 2 diabetic mice by inhibiting the MAPK/NF‐κB inflammatory pathway

导出原文传递

翻译打印收藏纠错

第一作者： Zhulin Shao

作者： Zhulin Shao ^[1] ; Xiaohong Li ; Xiangjin Xu ; Pin Chen

作者单位： Department of Endocrinology, 900 Hospital of the Joint Logistics Team,Fuzong Clinical Medical ^[1]

关键词 DPP‐4 inhibitor inflammation Linagliptin Psoriasis type 2 diabetes mellitus

发布时间 2023-01-14

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Drug Development Research

2022年83卷6期

1373-1382页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Drug Development Research

2022年83卷6期

1373-1382页

检索历史清除

DPP‐4 inhibitor linagliptin ameliorates imiquimod‐induced psoriasis‐like skin alterations in type 2 diabetic mice by inhibiting the MAPK/NF‐κB inflammatory pathway

Drug Development Research

相似文献

同项目论文

Drug Development Research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

DPP‐4 inhibitor linagliptin ameliorates imiquimod‐induced psoriasis‐like skin alterations in type 2 diabetic mice by inhibiting the MAPK/NF‐κB inflammatory pathway

Drug Development Research

相似文献

同项目论文

Drug Development Research

相关期刊

检索历史清除